Company news

Zelira Therapeutics Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

EDCDM Technology License Agreement Update

June 13, 2022

Zenivol Longitudinal, RWD Trial in Insomnia Results

June 7, 2022

Hope 1 Longitudinal, Real-World Data Trial in ASD Results

May 16, 2022

March 2022 Quarterly Activities Report

April 28, 2022

Appendix 4D & FY22 Interim Financial Report

February 28, 2022

ZLD: Zelira to acquire Health House International Limited

February 23, 2022

Zelira Therapeutics Ltd to acquire Health House

February 23, 2022

Appendix 4D & FY22 Interim Financial Report

February 23, 2022

December 2021 Quarterly Activities Report

January 30, 2022

Zelira receives $1.2 million cash R&D Tax Incentive

January 11, 2022

Partial Receipt Of Zeliras EDCDM Technology License Fee

January 9, 2022

Zelira expands into NZ via exclusive distribution agreement

December 15, 2021

ZLD Supports Levins Chronic Pain Trial Ethics Approval

December 1, 2021

Zelira Develops Technology and Signs New Licensing Deal

November 2, 2021

September 2021 Quarterly Activities Report

October 28, 2021

Zelira Raises US$5 Million from US Fund

October 19, 2021

Zelira Launches RAF FIVE Acne Treatment Products

September 22, 2021

Zelira enters Germany via Exclusive Distribution Agreement

September 19, 2021

Appendix 4C - quarterly

July 29, 2021

June 2021 Quarterly Activities Report

July 29, 2021

US Observational Clinical Pain Trial Receives IRB Approval

July 11, 2021

Cantor Fitzgerald - Investor Presentation

June 30, 2021

Research Demonstrates Significant Uptake of CBD Into Brain

June 18, 2021

Zelira to Launch CBD Toothpaste in the United Kingdom

June 14, 2021

ZLD and Levin Health to Conduct Chronic Pain Clinical Trial

June 2, 2021

Zeliras HOPE Range of Products Launches in Washington DC

May 5, 2021

March 2021 Quarterly Report

April 21, 2021

Zelira Announces Record Third Quarter Revenue

April 14, 2021

Appendix 4D & FY21 Interim Financial Report

February 22, 2021

Strategic Transition and Executive Changes

February 14, 2021

December 2020 Quarterly Report

January 28, 2021

Zelira Expands HOPE Distribution to Washington DC, USA

December 13, 2020

R&D Tax Incentive Refund

December 10, 2020

ZLD Partners with SprinJene to Launch CBD Toothpaste in US

December 1, 2020

Emyria Deal and Autism Observational Trial for HOPE Products

November 8, 2020

September 2020 Quarterly Report

October 29, 2020

HOPE launches in Australia after TGA approves release

October 26, 2020

Thorney Becomes a Substantial Strategic Investor in Zelira

September 22, 2020

Zenivol launches in Australia after TGA approves release

September 16, 2020

Zelira Forms Subsidiary to Launch Oral Care Products in USA

September 7, 2020

Appendix 4E & Financial Statements

August 28, 2020

HOPE Range Of Products Launches In Louisiana

August 19, 2020

ZLD Successfully Completes $8.75M Oversubscribed Placement

August 3, 2020

June 2020 Quarterly Report

July 30, 2020

Zelira Enters Deal to Develop Products For Vascular Diseases

July 21, 2020

Zelira Phase 1 Chronic Pain Trial Meets Clinical Endpoints

July 13, 2020

TasAlk to Manufacture Zeliras Insomnia and HOPE products

May 25, 2020

March 2020 Quarterly Report

April 29, 2020

Insomnia Trial Meets Primary and Secondary Endpoints

April 7, 2020

Appendix 4D & FY20 Interim Financial Report

February 28, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 29 decks. Every deck is listed under its year.